Charles Schwab Investment Management Inc. Has $7.75 Million Stock Holdings in 10x Genomics, Inc. (NASDAQ:TXG)

Charles Schwab Investment Management Inc. decreased its position in shares of 10x Genomics, Inc. (NASDAQ:TXG - Free Report) by 17.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 539,666 shares of the company's stock after selling 111,916 shares during the period. Charles Schwab Investment Management Inc. owned about 0.45% of 10x Genomics worth $7,750,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TXG. Atria Wealth Solutions Inc. grew its position in shares of 10x Genomics by 9.6% during the fourth quarter. Atria Wealth Solutions Inc. now owns 10,788 shares of the company's stock worth $155,000 after buying an additional 943 shares in the last quarter. First Horizon Advisors Inc. increased its position in shares of 10x Genomics by 53.3% in the 3rd quarter. First Horizon Advisors Inc. now owns 2,910 shares of the company's stock worth $66,000 after purchasing an additional 1,012 shares during the last quarter. Blue Trust Inc. raised its stake in shares of 10x Genomics by 73.1% in the 4th quarter. Blue Trust Inc. now owns 3,075 shares of the company's stock valued at $44,000 after purchasing an additional 1,299 shares in the last quarter. Sound Income Strategies LLC lifted its position in shares of 10x Genomics by 65.2% during the fourth quarter. Sound Income Strategies LLC now owns 3,370 shares of the company's stock worth $48,000 after purchasing an additional 1,330 shares during the last quarter. Finally, KBC Group NV lifted its position in shares of 10x Genomics by 57.3% during the fourth quarter. KBC Group NV now owns 5,072 shares of the company's stock worth $73,000 after purchasing an additional 1,847 shares during the last quarter. 84.68% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity

In other news, insider Benjamin J. Hindson sold 4,573 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $11.07, for a total transaction of $50,623.11. Following the sale, the insider now owns 335,324 shares in the company, valued at $3,712,036.68. The trade was a 1.35 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Serge Saxonov sold 5,092 shares of the firm's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $11.07, for a total transaction of $56,368.44. Following the completion of the transaction, the chief executive officer now directly owns 879,482 shares of the company's stock, valued at $9,735,865.74. This represents a 0.58 % decrease in their position. The disclosure for this sale can be found here. Insiders own 10.03% of the company's stock.

10x Genomics Stock Performance

Shares of TXG stock traded down $0.17 during mid-day trading on Thursday, hitting $9.41. 2,952,040 shares of the stock traded hands, compared to its average volume of 2,850,601. The firm has a market cap of $1.15 billion, a price-to-earnings ratio of -6.19 and a beta of 1.93. The company's 50-day simple moving average is $12.35 and its 200-day simple moving average is $15.26. 10x Genomics, Inc. has a twelve month low of $9.27 and a twelve month high of $38.49.

10x Genomics (NASDAQ:TXG - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.32) by ($0.08). 10x Genomics had a negative net margin of 29.90% and a negative return on equity of 25.40%. Analysts forecast that 10x Genomics, Inc. will post -1.43 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have commented on the company. Leerink Partnrs downgraded 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Thursday, February 13th. Morgan Stanley reduced their price objective on 10x Genomics from $28.00 to $26.00 and set an "overweight" rating on the stock in a research note on Friday, February 14th. Stifel Nicolaus lowered their target price on shares of 10x Genomics from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Thursday, February 13th. UBS Group dropped their target price on shares of 10x Genomics from $20.00 to $14.00 and set a "neutral" rating on the stock in a report on Thursday, February 13th. Finally, JPMorgan Chase & Co. decreased their price target on shares of 10x Genomics from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, February 13th. One analyst has rated the stock with a sell rating, nine have issued a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $20.21.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.